Home > News > Feasibility of New-generation Infrared Imaging Screening for Breast Cancer in Rural Communities
Breast Cancer, Radiology
Read Time: 9 mins

Feasibility of New-generation Infrared Imaging Screening for Breast Cancer in Rural Communities

Published Online: June 3rd 2011 US Oncological Review, 2010;6(1):60-4 DOI: https://doi.org/10.17925/OHR.2010.06.0.60
Authors: Francisco Gutierrez-Delgado, José G Vázquez-Luna
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Breast cancer is a major public health problem worldwide. Important advances have improved survival, but early detection remains the main clinical challenge in reducing mortality. Currently, mammography is the ‘gold standard’ tool for breast cancer screening. However, the search for an early breast cancer detection method is the subject of extensive research. Although infrared imaging or breast thermography for early breast cancer detection has been evaluated since the late 1950s, the negative results reported in 1979 by the Breast Cancer Detection and Demonstration Project decreased interest in this imaging modality. Advances in infrared imaging and reduced equipment costs have, however, renewed interest in breast thermography. Breast cancer in developing countries requires new strategies to increase early detection and access to care. In this article, we highlight the principles and advances of infrared imaging technology and describe our experience with new-generation infrared imaging for early breast cancer detection in rural communities in southern Mexico. Acknowledgement: This study was supported by a grant (2004-CO1-021) from the Council for Science and Technology (CONACYT)-MEXICO.

Keywords

Infrared imaging, breast thermography, breast cancer, breast cancer screening, thermography, thermal infrared imaging, medical infrared imaging

Article:

Breast cancer, the most common cancer and the second leading cause of death among women worldwide, remains an important public health problem. More than one million women are newly diagnosed with breast cancer each year, and approximately 500,000 women die annually from this malignancy. Advances in breast cancer therapy have led to improved survival in the last 10 years. However, early breast cancer detection continues to be a clinical challenge.1 Although mammography was approved by the US Food and Drug Administration (FDA) as the ‘gold standard’ tool for breast cancer screening, the limitations of this screening procedure are well known.2 Moreover, the World Health Organization (WHO) has recognized that mammography is not a viable option for many countries because it is an expensive screening tool that requires a large infrastructure and trained healthcare professionals.3 The search for a detection tool for early-stage breast cancer is the subject of extensive research. Efforts to develop an early breast cancer detection method have included digital mammography, computer-aided detection, ultrasound, magnetic resonance imaging (MRI), positron emission tomography (PET), electrical impedance imaging, and infrared (IR) imaging, alternately named thermography or breast thermography. Despite these imaging technologies receiving FDA approval as diagnostic adjuncts to mammography, currently there is no diagnostic tool capable of significantly reducing breast cancer mortality that benefits women at all ages, is non-invasive, has high-quality assurance, has high sensitivity and specificity, is inexpensive, and is easily trainable. Moreover, most imaging modalities, although promising, are too expensive for routine use. Advances in IR imaging and reduced equipment costs show promise as a feasible technology that could meet ideal characteristics for an early breast cancer detection tool. The incorporation of cameras with high-resolution digital imaging, high-speed image capture, image manipulation software, high-speed computers, and computer-aided detection are new technologies suitable for breast cancer screening. Diakides and Bronzino have provided a comprehensive review of recent advances in IR imaging.4 Low- and middle-income countries require new strategies to increase early breast cancer detection and access to care. In this article we review the role and feasibility of IR imaging for early breast cancer detection in rural communities in southern Mexico.

Definition of Infrared Imaging

Clinical thermography is a non-invasive, non-contact, and non-ionizing radiation imaging technique that detects, records, and forms an image of the temperature distribution on the surface of the body. IR imaging is not related to morphology; it is a functional imaging technology. The physics rationale is that all objects with a temperature above absolute zero (-273°K) emit IR radiation from their surface. Because the emissivity of human skin is high, it can be converted into temperature values. IR imaging equipment has been designed to provide both qualitative and quantitative information on temperature patterns. In the electromagnetic spectrum, the IR are located between visible and microwave spectral regions covering wavelengths that range between 0.75 and 1,000μm. The full IR spectral region is subdivided into: near IR (NIR), which covers wavelengths between 0.75 and 1.4μm; short-wave IR (SWIR), from 1.4 to 3.0μm; mid-wave IR (MWIR), between 3.0 and 8.0μm; long-wave IR (LWIR), from 8 to 12μm; and far IR (FIR), beyond 12μm. Despite the new generation of IR cameras detecting the full spectral region, for medical IR imaging purposes LWIR (or body IR rays) is the most important IR spectral region. Thermal IR (TIR) refers to the region that covers wavelengths beyond 1.4μm where the IR emission is heat or thermal radiation and covers the SWIR, MIWR, LWIR, and FIR regions. IR rays cannot be detected by the human eye; however, IR radiation can be detected using IR cameras and detectors.4–9

Clinical Infrared Imaging Equipment

First-generation IR cameras were large and heavy, and were expensive because they required the use of a cooling system in the form of a nitrogen or compressed-air cooling bottle. Scanning mirrors were incorporated to generate the picture. Advances in detector technology and microelectronics, favored the incorporation of uncooled thermal detectors and 2D imaging device types as a focal plane array (FPA) that is sensitive in the IR spectrum, avoiding the use of mirrors and improving image quality. Currently, the thermal sensitivity of the uncooled cameras is 0.05 or 0.02ºC and the FPA detector detects wavelengths from 3–5 or 8–12 to 3.0μm. Cancer cells can be imaged as hotspots in the IR images due to their high metabolic rates and angiogenesis, generating a higher temperature than the normal cells around them. Because of the advances in detector technology it has been reported that the average breast cancer tumor size undetected by new IR cameras is 1.28cm, versus 1.66cm by mammography.10 Moreover, new IR cameras are much smaller, lighter, more reliable, and less expensive. The new generation of IR cameras has benefited from important advances in computer and information technology. IR cameras coupled with high-speed computers, high-speed image capture systems, and high-resolution digital imaging generate much smoother and clearer pictures.4,9

Methods of Acquiring Infrared Images

The most common methods of acquiring IR images to detect breast cancer are classic static thermal imaging and active or dynamic IR imaging. Static thermography monitors and measures temporal changes in the temperature of selected areas. It has been the most frequently used method in clinical studies of breast thermography. Dynamic thermal assessment (DTA), another term for dynamic thermal imaging (DTI), monitors physiological processes and measures temperature distribution over certain areas.9 DTA could provide more information about angiogenesis and metabolic changes associated with breast cancer. Although promising, DTA has not yet been sufficiently evaluated in clinical trials. Other innovative IR imaging methods such as active dynamic thermal (ADT) IR imaging or thermographic non-destructive testing (TNDT), thermal tomography or thermal texture mapping, thermal multispectral imaging, and 3D IR are still under intensive research and development.4–6,9

Image Processing and Analysis

Advanced image processing, image manipulation software, and computer-aided detection are feasible tools that play an important role in the analysis and standardization of IR imaging. The incorporation of both image processing techniques and smart processing approaches, also known as artificial intelligence, will help to reduce the false-positive diagnosis rate and avoid bias associated with physician analysis of IR images. Asymmetry analysis, artificial neural network classification, smart brain-like neural network algorithms, and automatic target recognition are technologies under development and evaluation.9 Since thermograms are recorded and stored in digital format, the organization of larger IR image databases is a feasible option for standardization of IR imaging. The Digital Imaging and Communications in Medicine (DICOM) medical imaging standard emerges as a feasible option for a standardized thermogram format for storage and communication of thermograms.11

Infrared Imaging in Medicine

IR imaging has been evaluated in medicine since the late 1950s when military developments in IR surveillance were transferred to medicine. After the first report by Lawson in 1956,12 IR imaging was mainly used in early breast cancer detection, but years later was reported to have clinical utility in different medical applications, such as diseases of the skeletal and neuromuscular systems, rheumatology, detection and diagnosis of deep venous thrombosis, diabetic microangiopathy, pain management and control, skin temperature and metabolism during exercise, coronary bypass operations, and orthopaedic and urological surgery.4,13 DTI has been applied to evaluate the response of soft-tissue sarcomas to chemotherapy and monitor angiogenesis activity in patients with Kaposi’s sarcomas.14,15 IR functional imaging has also recently been evaluated as a mass screening tool of fever for infectious disease outbreak.16

Infrared Imaging and Early Breast Cancer Detection—Early Experience

Between 1956 and 1963 pioneer studies reported by Lawson demonstrated that breast cancer increases regional skin temperature and can be accurately measured by IR imaging.12,17,18 In 1963, Lawson and Chughtai also suggested that the temperature changes observed could be explained by both increased vascular flow and increased metabolism.19 Despite the biological mechanism explaining these temperature changes remaining unclear, it was suggested that the elevation in temperature could be due to either hypervascularity as a result of tumor angiogenesis or nitric-oxide-mediated vasodilatation resulting from nitric oxide release from breast tumor cells. The role of angiogenesis in cancer,20 and particularly in early breast cancer, was established several years later.21–24 Today, it is also known that nitric oxide is a potent neurotransmitter that induces vasodilatation. All three isoforms of nitric oxide synthase (NOS)—inducible (iNOS), endothelial (eNOS), and neuronal (nNOS)—have been detected in tumor cells and could be involved in promoting or inhibiting cancer;29–31 NOS has also been identified in breast tumor cells.25–28 Nitric oxide produced by tumor cells leads to vasodilatation and that mechanism could explain why breast cancer is associated with local hyperthermia. This hypothesis has been experimentally corroborated by using digital IR imaging.32
In the 1960s and early 1970s, thermography was actively evaluated as a feasible screening tool for early breast cancer detection.33,34 Approximately 3,000 thermography clinics were operating in the US during this time.7,8 However, the negative results reported in 1977 by Feig35 and in 1979 by the Breast Cancer Detection and Demonstration Project36 decreased interest in breast thermography. In these studies, which evaluated the roles of physical examination, mammography, and first-generation thermal IR imaging in breast cancer detection, thermography showed high false-positive rates and low sensitivity. Although thermal IR imaging was approved by the FDA in 1982 for use as an adjunctive breast cancer screening procedure,36 this diagnostic approach has been abandoned.

Infrared Imaging and Early Breast Cancer Detection in the 21st Century

To date, thermography has been considered an experimental and unproven tool for early breast cancer detection because of a lack of well-designed and controlled clinical trials evaluating its role for either screening or diagnosis. IR imaging has dramatically improved and interest in this technology has been renewed. However, in the last decade the new generation of IR cameras, coupled with the advantages of computer and information technology, have not been evaluated in studies designed as clinical trials, except one reported by Parisky et al.37 In that study, 769 patients diagnosed as having mammographically suspicious lesions were evaluated by computerized IR imaging analysis, as was a subgroup of 448 patients who had micro-calcifications but were assessed as false-negative by IR imaging. The index of suspicion for the whole group and the group with microcalcifications was, respectively: sensitivity 97 and 99%; specificity 14 and 18%; negative predictive value 95 and 99%; and positive predictive value 24 and 27%. The role of IR imaging as either a screening or a diagnostic tool for breast cancer was reviewed by Kerr,38 but there were no significant studies found. It is important to note that between 1985 and 2004 the only study that evaluated IR imaging for breast cancer screening did not show evidence of benefit.39 However, the study by Parisky et al.37 and the retrospective case–control study reported in 1998 by Keyserlingk et al.40 documented that IR imaging provides an adjuvant benefit. In the last five years, clinical trials evaluating the role of IR imaging in breast cancer have not been reported. Currently, there is no evidence to support the role of IR imaging for screening or as an adjuvant diagnostic tool. However, the limitations of mammography as an early breast cancer detection tool necessitate evaluation of the new generation of IR cameras in well-designed and controlled clinical trials.

Experience of the Center for the Study and Prevention of Cancer with New-generation Infrared Imaging Screening for Breast Cancer in Rural Communities
Breast Cancer in Mexico

Breast cancer is the second highest cause of death from cancer among Mexican women. The median age at diagnosis is 51 years, and 45.5% of all breast carcinomas develop in patients <50 years of age.41 Up to 90% of women are diagnosed as having advanced disease. However, only 7% of women >50 years of age report having had a mammogram. Although rural women are generally considered to be at lower risk for breast cancer than women living in the main cities, the incidence of this malignancy has been rising rapidly in rural populations. A low frequency in the practice of mammography, ranging between 12 and 18%, has been reported.42,43 These findings can be explained by lack of availability of medical resources, including insufficient mammography equipment and trained healthcare professionals. With the aim of improving early breast cancer detection in this population, the Center for the Study and Prevention of Cancer (CEPREC) has designed educational, preventive, and early detection programs. As part of this public health strategy, we have evaluated the feasibility of new-generation IR imaging as a screening tool for breast cancer.44

Patients and Methods

From November 2006 to December 2008, women attending cancer screening programs at our clinic were invited to participate in this study and offered clinical breast examination (CBE) followed by breast thermography and mammography, and biopsy if indicated. CBE and breast thermography were correlated with mammography and histological diagnosis.

Infrared Camera Characteristics

IR imaging was obtained using an IR camera (DL-700; 320*240 UFPA, Zhejiang Dali Technology Co., Ltd). The main characteristics are: detector type FPA; uncooled microbolometer; resolution 320×240; spectral 240; spectral range 8–14μm; thermal time constant 4ms; lens field of view 20.4–15.4°; focus range 1m–∞; and thermal sensitivity 0.08–30oC.

Patient Position and Image Capture

In order to increase accuracy and precision, IR imaging was performed in a controlled environment. Temperature was maintained between 18 and 23oC (within }0.1oC) and the humidity was about 60}5%. After clinical breast examination, patient preparation included an acclimatization period in the imaging room of at least 15 minutes. Then, with the purpose of facilitating anatomical presentation of the breasts, the patient placed her hands on top of her head. The bilateral frontal breast, the right and left oblique views, and right and left single breast close-up views, if indicated, were included in the series.45

Image Processing and Analysis

In a first step, images captured from the IR camera were obtained in rpt format and then converted into bitmap (BMP) file format, as shown in Figure 1 (bilateral frontal view), Figure 2 (right oblique view), and Figure 3 (left oblique view). On the basis of these images, a preliminary IR imaging diagnosis was established according to thermobiological criteria (TH):45 TH1, normal uniform non-vascular; TH2, normal uniform vascular; TH3, equivocal; TH4, abnormal; or TH5, severely abnormal. The results reported in this study are based on this classification. An ongoing second step of this study is the image processing of TH3, TH4, and TH5 thermograms using image manipulation software developed by us and based on image filtering that incorporates the full IR spectrum and an algorithm. Preliminary image processing with this software allows us to detect hotspots (see Figure 4) that cannot be observed in the conventional thermogram (see Figure 1).

Results

Overall, 911 women (100%) with a median age of 44 years were evaluated. Five hundred and three (55%) were 40 years of age or older. The median age of this group was 58 years (range 40–83). Two hundred and eighty-seven (57%) women were 40–49 years of age, 154 (31%) were between 50 and 59 years of age, and 62 (12%) were over 60 years of age. Cancer was diagnosed in 14 women (2.7%); a TH5 diagnosis was previously established in 13 (92.85%) of these 14 women. Cancer was diagnosed in three (1.18%) of 253 women 30–39 years of age; the three women (100%) had a TH5 diagnosis. Overall, cancer was diagnosed in 17 (2.2%) of 756 women >30 years of age. Sixteen of 17 women (94%) were previously diagnosed as TH5 using IR imaging. Cancer was not found in the group of women under 30 years of age.

Conclusions

In this study, breast cancer was diagnosed in 2.2% of women over 30 years of age. Ninety-four percent of women diagnosed as having cancer were previously diagnosed using new IR imaging technology. These findings are encouraging and require independent confirmation, assessing larger patient numbers in the context of well-designed and controlled clinical trials. IR imaging emerges as a potential screening tool for early detection of breast cancer. However, the development of international co-operation among physicians and IR imaging centers is required. ■

Article Information:
Disclosure

The authors have no conflicts of interest to declare.

Correspondence

Francisco Gutierrez-Delgado, MD, PhD, FACP, Centro de Estudios y Prevencion del Cancer (CEPREC), Bugambilias 30, Fraccionamiento La Riviera, Juchitan, Oaxaca, CP 70000, Mexico. E: fgutierrez@ceprec.org

Received

2009-09-03T00:00:00

References

  1. www.who.int/mediacentre/factsheets/fs297/en/index.html (accessed July 31, 2009).
  2. Breast imaging and related technologies. In: Nass SJ, Henderson IC, Lashpf JC (eds), Mammography and Beyond: Developing Technologies for the Early Detection of Breast Cancer, Committee on the Early Detection of Breast Cancer, National Cancer Policy Board, Institute of Medicine and Commission on Life Sciences, National Research Council, Washington: National Academy Press, 2001;55–104.
  3. www.who.int/cancer/detection/breastcancer/en/index.html (accessed July 31, 2009).
  4. Diakides NA, Diakides M, Lupo JC, et al., Advances in medical infrared imaging. In: Diakides NA, Bronzino JD (eds), Medical Infared Imaging, Boca Raton: CRC Press, 2008;1–13.
  5. Anbar M, Dynamic thermal assessment. In: Diakides NA, Bronzino JD (eds), Medical Infared Imaging, Boca Raton: CRC Press, 2008;8–23.
  6. Nowakowski A, Quantitative active dynamic thermal IRimaging and thermal tomography in medical diagnostics. In: Diakides NA, Bronzino JD (eds), Medical Infared Imaging, Boca Raton: CRC Press, 2008;7–29.
  7. Foster KR, Thermographic detection of breast cancer, IEEE Eng Med Biol, 1998;17:10–4.
  8. William C, Amalu WC, Hobbins WB, et al., Infrared imaging of the breast: a review. In: Diakides NA, Bronzino JD (eds), Medical Infared Imaging, Boca Raton: CRC Press, 2008;9–22.
  9. Qi H, Kuruganti PT, Snyder WE, Detecting breast cancer from thermal infrared images by asymmetry analysis. In: Diakides NA, Bronzino JD (eds), Medical Infared Imaging, Boca Raton: CRC Press, 2008;11–4.
  10. Keyserlingk JR, Ahlgren PD, Yu E, et al., Functional infrared imaging of the breast, IEEE Eng Med Biol, 2000;19:30–41.
  11. Schaefer G. In: Diakides NA, Bronzino JD (eds), Medical Infared Imaging, Boca Raton: CRC Press, 2008;15–23.
  12. Lawson RN, Implications of surface temperatures in the diagnosis of breast cancer, Can Med Assoc J, 1956;75:309.
  13. Sengupta S, Webb DR, Use of a computer controlled bipolar diathermy system in radical prostatectomies and other open urological surgery, ANZ J Surg, 2001;71:538–40.
  14. Janicek MJ, Waxman A, Janicek MR, Demetri GD, Assessment of early response to therapy in sarcomas: dynamic infrared imaging (DIRI), computerized tomography (CT) and F-18 FDG positron emission tomography (PET), American Society of Clinical Oncology (ASCO) Annual Meeting, 2001, Abstract #1390.
  15. Hassan M, Little RF, Vogel A, et al., Quantitative assessment of tumor vasculature and response to therapy in Kaposi’s sarcoma using functional noninvasive imaging, Technol Cancer Res Treat, 2004;3:451–7.
  16. Ng EY-K, Wiryani M, Wong BS, Study of facial skin and aural temperature using IR with and w/o TRS, IEEE Eng Med Biol Mag, 2006;25:68–74.
  17. Lawson RN, Thermography – a new tool in the investigation of breast lesions, Can Serv Med, 1957;13:517.
  18. Lawson RN, A new infrared imaging device, Can Med Assoc J, 1958;79:402.
  19. Lawson RN, Chughtai MS, Breast cancer and body temperatures, Can Med Assoc J, 1963;88:68–70.
  20. Folkman J, Tumor angiogenesis: therapeutic implications, N Eng J Med, 1971;285:1182–6.
  21. Weidner N, Semple JP, Welch WR, et al., Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma, N Engl J Med, 1991;324:1–8.
  22. Weidner N, Folkman J, Pozza F, et al., Tumor angiogenesis: A new significant and independent prognostic indicator in earlystage breast carcinoma, J Natl Cancer Inst, 1992;84:1875–87.
  23. Guidi AJ, Fischer L, Harris JR, et al., Microvessel density and distribution in ductalcarcinoma in situ of the breast, J Natl Cancer Inst, 1994;86:614–9.
  24. Guidi AJ, Schnitt SJ, Fischer L, et al., Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast, Cancer, 1997;80:1945–53.
  25. Freeman G, Dyer RL, Juhos L, et al., Identification of nitric oxide (NO) in human blood, Arch Environ Health, 1978;33: 19–23.
  26. Thomsen LL, Lawton FG, Knowles RG, et al., Nitric oxide synthase activity in human gynecological cancer, Cancer Res, 1994;54:1352–4.
  27. Anbar M, Hyperthermia of the cancerous breast – analysis of mechanism, Cancer Letters, 1994;84:23–9.
  28. Jenkins DC, Charles IG, Thomsen LL, et al., Roles of nitric oxide in tumor growth, Proc Natl Acad Sci USA, 1995;92:4392–6.
  29. Thomsen LL, Miles DW, Happerfield L, et al., Nitric oxide synthase activity in human breast cancer, Br J Cancer, 1995;72:41–4.
  30. Zeillinger R, Tantscher E, Schneeberger C, et al., Simultaneous expression of nitric oxide synthase and estrogen receptor in human breast cancer cell lines, Breast Cancer Res Treatment, 1996;40:205–7.
  31. Duenas-Gonzalez A, Isales CM, del Mar Abad-Hernandez M, et al., Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease, Modern Pathology, 1997;10:645–9.
  32. Xie W, McCahon P, Jakobsen K, Parish C, Evaluation of the ability of digital infrared imaging to detect vascular changes in experimental animal tumours, Int J Cancer, 2004;108:790–4.
  33. Gershen-Cohen J, Haberman J, Brueschke EE, Medical thermography: a summary of current status, Radiol Clin North Am, 1965;3:403–31.
  34. Haberman J, The present status of mammary thermography, CA Cancer J Clin, 1968;18:314–21.
  35. Feig SA, Shaber GS, Schwartz GF, et al., Thermography, mammography, and clinical examination in breast cancer screening. Review of 16,000 studies, Radiology, 1977;12:123–7.
  36. Report of the Working Group to Review the National Cancer Institute Breast Cancer Detection Demonstration Projects, J Natl Cancer Inst, 1979;62:641.
  37. Parisky YR, Sardi A, Hamm R, et al., Efficacy of computerized infrared imaging analysis to evaluate mammographically suspicious lesions, Am J Roentgenol, 2003;180:263–9.
  38. Kerr J, Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer, New Zealand Health Technology Assessment Department of Public Health and General Practice Christchurch School of Medicine Christchurch, NZ, Division of Health Sciences, University of Otago, NZHTA Tech Brief Serices, 2004;3.
  39. Williams KL, Phillips BH, Jones PA, et al., Thermography in screening for breast cancer, J Epidemiol Comm Health, 1990;44:112–3.
  40. Keyserlingk JR, Ahlgren PD, Yu E, Belliveau N, Infrared imaging of the breast: Initial reappraisal using high-resolution digital technology in 100 successive cases of stage I and II breast cancer, Breast J, 1998;4:245–51.
  41. Rodríguez-Cuevas S, Macías CG, Franceschi D, Labastida S, Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries, Cancer, 2001;91:863–8.
  42. Sosa-Rubí SG, Walker D, Serván E, Performance of mammography and Papanicolauamong rural women in Mexico, Salud Publica Mex, 2009;51(Suppl. 2):S236–45.
  43. Saldana-Tellez M, Marcial-Toledo S, Perez-Romero J, et al., Knowledge and beliefs about breast cancer in rural women and indigenous population of Southern Mexico, J Clin Oncol, 2009;27:15s, abstract 1533 .
  44. Gutierrez-Delgado F, Vázquez-Luna J, Venegas-Hernández L, et al., Feasibility of thermal infrared imaging screening for breast cancer. The experience of the Centro de Estudios y Prevencion del Cancer (CEPREC), J Clin Oncol, 2009;27:15s, abstract 1521.
  45. Hobbins WB, Abnormal thermogram—significance in breast cancer. Interamer, J Rad, 1987;12:337.

Further Resources

Share this Article
Related Content In Radiology
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72